i hate writing essays essay on andrew jackson how to do a dissertation bibliography college admission essays for sale dissertation 100 seiten to buy dissertation best dissertation writing 5 business plan for home health care
Skip to main content

Point-of-care blood test for early sepsis diagnosis

Ref-Nr: TA-B79000


Kurzfassung

  • Diagnostic test for suspected sepsis (bacterial, viral incl. SARS-CoV, fungal)
  • Easy and broadly applicable test, small blood sample volumes needed
  • Allows much earlier diagnosis (~36h) than currently possible

 


Hintergrund

Sepsis is a life-threatening multiorgan failure caused by an excessive, dysregulated immune reaction following an infection. Comprising over 20 million annual cases and estimated 8 million cases of death worldwide, sepsis is a major contributor to the global disease burden. Early diagnosis is crucial for an immediate therapy onset and hence patients' survival. However, a precise diagnosis is still hampered by the lack of specific symptoms. The challenge is thus to develop a tool for the early diagnosis of sepsis or a developing sepsis; ideally a simple, quick point-of-care test for emergency rooms and doctor’s practices.


Bilder & Videos


Lösung

The innovation describes a novel diagnostic tool for sepsis based on altered platelet function. Patients’ blood samples are stimulated with specific agonists, the readout can be done by e.g. ELISA, aggregometry, or FACS. The test can be used for all cases of suspected sepsis regardless of the focus of infection (respiratory, urogenital, abdominal), or source of infection (gram-positive, gram-negative, SARS-CoV-2, fungal) and can provide additional clinical information about disease severity and patient prognosis. The method allows medical personnel to make coherent decisions at a much earlier time point than usual sepsis diagnostic methods, e.g. about the need for an immediate start of antibiotic therapy, the transfer to an ICU or close monitoring of high-risk patients.


Vorteile

The innovation can be used for early identification of a developing or manifested sepsis. Potential applications are:

  • Blood test kits for hospitals, medical practices, emergency departments
  • Point-of-care test devices

Bayerische Patentallianz GmbH


089 5480177-0
kontakt@baypat.de
www.baypat.de
Adresse
Destouchesstr. 68
80796 München



Entwicklungsstand

Machbarkeit


Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen